Schwab Charles Investment Management Inc. Raises Stake in Dermira, Inc. (DERM)

Schwab Charles Investment Management Inc. increased its position in shares of Dermira, Inc. (NASDAQ:DERM) by 24.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 140,495 shares of the biopharmaceutical company’s stock after acquiring an additional 27,259 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.34% of Dermira worth $4,095,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of DERM. BlackRock Inc. lifted its stake in shares of Dermira by 4,816.7% during the first quarter. BlackRock Inc. now owns 3,392,848 shares of the biopharmaceutical company’s stock valued at $115,729,000 after acquiring an additional 3,323,841 shares during the period. Vanguard Group Inc. lifted its stake in shares of Dermira by 20.7% during the first quarter. Vanguard Group Inc. now owns 1,272,700 shares of the biopharmaceutical company’s stock valued at $43,412,000 after acquiring an additional 217,943 shares during the period. State Street Corp lifted its stake in shares of Dermira by 15.6% during the first quarter. State Street Corp now owns 593,655 shares of the biopharmaceutical company’s stock valued at $20,251,000 after acquiring an additional 79,994 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Dermira during the first quarter valued at $2,346,000. Finally, Geode Capital Management LLC lifted its stake in shares of Dermira by 27.6% during the first quarter. Geode Capital Management LLC now owns 252,345 shares of the biopharmaceutical company’s stock valued at $8,607,000 after acquiring an additional 54,646 shares during the period. 97.56% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2017/10/17/schwab-charles-investment-management-inc-raises-stake-in-dermira-inc-derm.html.

In related news, Director Fred B. Craves bought 30,000 shares of the business’s stock in a transaction on Monday, August 14th. The shares were purchased at an average cost of $23.03 per share, with a total value of $690,900.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Thomas G. Wiggans sold 9,500 shares of Dermira stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $27.51, for a total value of $261,345.00. The disclosure for this sale can be found here. Insiders have sold a total of 24,300 shares of company stock worth $682,651 over the last ninety days. Company insiders own 13.30% of the company’s stock.

Shares of Dermira, Inc. (DERM) opened at 28.21 on Tuesday. The company’s market cap is $1.17 billion. Dermira, Inc. has a 12-month low of $21.35 and a 12-month high of $38.75. The company has a 50-day moving average price of $26.17 and a 200-day moving average price of $28.34.

Dermira (NASDAQ:DERM) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.04). The company had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.00 million. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. On average, analysts predict that Dermira, Inc. will post ($4.20) earnings per share for the current year.

Several equities analysts have recently issued reports on DERM shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $45.00 price target on shares of Dermira in a research note on Tuesday, September 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 price target on shares of Dermira in a research note on Sunday, September 17th. BidaskClub raised Dermira from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Evercore ISI started coverage on Dermira in a research note on Thursday, June 29th. They set an “outperform” rating and a $48.00 price target on the stock. Finally, Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research note on Thursday, Augu

Several other institutional investors and hedge funds have also recently modified their holdings of DERM. BlackRock Inc. lifted its stake in shares of Dermira by 4,816.7% during the first quarter. BlackRock Inc. now owns 3,392,848 shares of the biopharmaceutical company’s stock valued at $115,729,000 after acquiring an additional 3,323,841 shares during the period. Vanguard Group Inc. lifted its stake in shares of Dermira by 20.7% during the first quarter. Vanguard Group Inc. now owns 1,272,700 shares of the biopharmaceutical company’s stock valued at $43,412,000 after acquiring an additional 217,943 shares during the period. State Street Corp lifted its stake in shares of Dermira by 15.6% during the first quarter. State Street Corp now owns 593,655 shares of the biopharmaceutical company’s stock valued at $20,251,000 after acquiring an additional 79,994 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Dermira during the first quarter valued at $2,346,000. Finally, Geode Capital Management LLC lifted its stake in shares of Dermira by 27.6% during the first quarter. Geode Capital Management LLC now owns 252,345 shares of the biopharmaceutical company’s stock valued at $8,607,000 after acquiring an additional 54,646 shares during the period. 97.56% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2017/10/17/schwab-charles-investment-management-inc-raises-stake-in-dermira-inc-derm.html.

In related news, Director Fred B. Craves bought 30,000 shares of the business’s stock in a transaction on Monday, August 14th. The shares were purchased at an average cost of $23.03 per share, with a total value of $690,900.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Thomas G. Wiggans sold 9,500 shares of Dermira stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $27.51, for a total value of $261,345.00. The disclosure for this sale can be found here. Insiders have sold a total of 24,300 shares of company stock worth $682,651 over the last ninety days. Company insiders own 13.30% of the company’s stock.

Shares of Dermira, Inc. (DERM) opened at 28.21 on Tuesday. The company’s market cap is $1.17 billion. Dermira, Inc. has a 12-month low of $21.35 and a 12-month high of $38.75. The company has a 50-day moving average price of $26.17 and a 200-day moving average price of $28.34.

Dermira (NASDAQ:DERM) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.04). The company had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.00 million. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. On average, analysts predict that Dermira, Inc. will post ($4.20) earnings per share for the current year.

Several equities analysts have recently issued reports on DERM shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $45.00 price target on shares of Dermira in a research note on Tuesday, September 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 price target on shares of Dermira in a research note on Sunday, September 17th. BidaskClub raised Dermira from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Evercore ISI started coverage on Dermira in a research note on Thursday, June 29th. They set an “outperform” rating and a $48.00 price target on the stock. Finally, Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Four research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Dermira currently has an average rating of “Hold” and an average target price of $44.40.

Dermira Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira, Inc. (NASDAQ:DERM).

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply